Dr. Reddy’s Announces the Launch of Sumatriptan Injection USP, Autoinjector System

  Dr. Reddy’s Announces the Launch of Sumatriptan Injection USP, Autoinjector
  System

Business Wire

HYDERABAD, India -- February 26, 2014

Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched
Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous
Use, a therapeutic equivalent generic version of IMITREX STATdose ^ Pen^®
(sumatriptan succinate) 6 mg/0.5 mL in the US market on February 25, 2014,
following the approval by the United States Food & Drug Administration
(USFDA).

The IMITREX STATdose ^ Pen^® (sumatriptan succinate) brand and generic
combined had U.S. sales of approximately $169 Million MAT for the most recent
twelve months ending in December 2013 according to IMS Health*.

Dr. Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 mL is
available in a carton containing 2 single-dose prefilled syringes.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy's

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infective. Major markets
include India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets.

IMITREX STATdose ^ Pen^® is a registered trademark of Glaxo Group Limited
*IMS National Sales Perspectives: Retail and Non-Retail MAT December 2013

Contact:

Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye
+91-40-66834297
kedaru@drreddys.com
or
Saunak Savla
+91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA)
+1 609-375-9831
mkalawadia@drreddys.com
or
Media:
SVS Chowdary
+91-40-49002448
chowdaryl@drreddys.com
 
Press spacebar to pause and continue. Press esc to stop.